Major depression drug recalled over wrong dosage.
Several pharma makers recalled more lots of Ranitidine due to a carcinogenic impurity, while one pharma maker recalled a drug to treat depression.
Denton Pharma, Inc. dba Northwind Pharmaceuticals voluntarily recalled all unexpired lots of Ranitidine Tablets 150 mg. and 300 mg. to the consumer level, due to the presence or potential presence of N-nitrosodimethylamine (NDMA), the pharma maker said in a press release.
Related: Drugstore Retailers Pull Zantac As Recalls Expand
NDMA is classified as a probable human carcinogen, based on results from laboratory tests.
Appco Pharma LLC is also voluntarily recalling all quantities and lots, within expiry, of Ranitidine Hydrochloride Capsules to the consumer level due to potential NDMA.
Appco’s marketing partner, ANI Pharmaceuticals Inc., will be notifying its distributors and customers by phone and in writing to immediately discontinue distribution of the specific lots being recalled and to notify their sub-accounts.
The FDA first warned about NDMA in Ranitidine products, including Zantac, this fall. Since then, many ranitidine products have been recalled.
Related: Cancer-Linked Impurity Found In Heartburn Drug
Meanwhile, Aurobindo Pharma USA is voluntarily recalling a lot of Mirtazapine tablets for major depressive disorder due to a label error on declared strength. Bottles labeled as Mirtazapine 7.5 mg. may actually contain 15 mg. tablets.
“Taking a higher dose than expected may increase risk of sedation, agitation, increased reflexes, tremor, sweating, dilated pupils, gastrointestinal distress, nausea, constipation and more. Unexpected levels of sedation in particular can contribute to falls in the elderly or motor vehicle accidents in adults,” Aurobindo said in a press release.
The affected lot number for both Mirtazapine Tablets 7.5 mg. and Mirtazapine Tablets 15 mg. are 03119002A3, with an expiration date of 03/2022.
Read more: Manufacturer Recalls Several Compounded Drugs Over Sterility Issues
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More